NCT07236190

Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Early Phase Biomarker-based Trial of NPC-1 for Alzheimer's Disease Pathology

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Massachusetts General Hospital · Academic / Other
• Sex: All
• Age: 55 Years
• Healthy volunteers: Not accepted

Summary

The goal of this early phase, open-label, single arm clinical trial is to determine the 6-month effects and tolerability of NPC1 (parthenolide and ipriflavone) on biomarkers of Alzheimer's Disease among adults with objective indicators of seeding AD pathology that also have subjective cognitive concerns, Mild Cognitive Impairment, or Alzheimer's Disease (AD)

Conditions

• Alzheimer Disease
• Mild Cognitive Impairment (MCI)
• Subjective Cognitive Complaints (SCCs)

Interventions

Type	Name	Description
DRUG	NPC1	NPC1 (parthenolide and ipriflavone)
DRUG	NPC1-Placebo/Control	Participants with undergo serial blood draws off active drug

Timeline

• Start date: 2026-04-01
• Primary completion: 2027-06-01
• Completion: 2027-06-01
• First posted: 2025-11-19
• Last updated: 2026-04-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study